Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442366 | 0.80 | MAOB (0.53) | MAOBMRGPRX4TP53PKMNFKB1 | |
| SCHEMBL1525379 | 0.78 | MAOB (0.45) | MAOBCYP4F2CYP4A11TP53PKM | |
| SCHEMBL68412 | 0.77 | L3MBTL1 (0.50) | MAOBCYP4F2CYP4A11PKMNFKB1 | |
| SCHEMBL28384845 | 0.77 | MAOB (0.41) | MAOBPKMNFKB1NFKB2RELA | |
| SCHEMBL17288159 | 0.76 | GAA (0.55) | TP53SMN1; SMN2PTPN1 | |
| SCHEMBL1008116 | 0.76 | LTB4R (0.61) | MAOBCYP4F2CYP4A11PKMSMN1; SMN2 | |
| SCHEMBL13735210 | 0.76 | MRGPRX4 (0.64) | CYP4F2CYP4A11MRGPRX4TP53PKM | |
| SCHEMBL30697582 | 0.75 | PRMT5 (0.60) | MAOBPRMT5FFAR1P4HTM | |
| SCHEMBL25107493 | 0.74 | MAOB (0.43) | MAOBPKMNFKB1NFKB2RELA | |
| SCHEMBL15424203 | 0.74 | LTA4H (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | MAOB 230/4885CYP4F2 20/4885CYP4A11 2/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | MAOB 230/4885CYP4F2 20/4885CYP4A11 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.